| Gene symbol | KRAS | Synonyms | C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | KRAS proto-oncogene, GTPase | ||||
| GTO ID | GTC1362 |
| Trial ID | NCT01188785 |
| Disease | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer |
| Altered gene | KRAS |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | siG12D LODER |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas |
| Year | 2011 |
| Country | Israel |
| Company sponsor | Silenseed Ltd |
| Other ID(s) | SLSG12D |
| Cohort1: siG12D LODER_dose level 1 | |||||||||||
|
|||||||||||
| Cohort2: siG12D LODER_dose level 2 | |||||||||||
|
|||||||||||
| Cohort3: siG12D LODER_dose level 3 | |||||||||||
|
|||||||||||